Other

Decipher Biosciences, Inc.

University of Michigan

Shuang Zhao

Elai Davicioni

H Alan Mantooth

Nicholas Erho

Felix Y Feng

Audrey Dearien

Roger A Dougal

Hussam Al-Deen Ashab

Homer Alan Mantooth

Janviere Umuhoza

Sei-Won Laura Chang

Yuzhi Zhang

Stephen Joe Moquin

S Laura Chang

Lori Pierce

Felix Feng

Corey Speers

The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of progression of cancer in a subject. The invention also provides biomarkers that define subgroups of prostate cancer, clinically useful classifiers for distinguishing prostate cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping prostate cancer in a subject. Classifiers for subtyping a prostate cancer are provided. Methods of treating cancer based on molecular subtyping are also provided.

Subtyping prostate cancer to predict response to hormone therapy

An improved gate driver using a microcontroller (uC), a voltage selector (VS), an adjustable voltage regulator (AVR), and an auxiliary current sinking circuit (ACSC) to actively provide selectable drive signals either higher, lower or equal to the basic on voltage and off voltage drive signals for a selected semiconductor device thereby providing an active voltage-mode gate driver for actively speeding up or slowing both the on time and off time transitions of a semiconductor.

Intelligent multi-level voltage gate driving system for semiconductor power devices

The present invention is directed to an improved smart green power node using predictive switching, predictive operation at a daily and hourly level, and both grid connected and island operating modes with built-in cybersecurity.

Smart green power node

Methods, compositions, and kits for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to a genomic signature based on expression levels of DNA Damage Repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy.

Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy

Growing community of inventors

Gardena, CA, United States of America

Shuang Zhao